Toujeo Dosing Calculator
Calculate the suggested starting dose for your patients with T2DM
Once-daily Toujeo should be injected at the same time each day (N=30)
Study Design
Clamp Study I: The pharmacodynamics of Toujeo at steady state after 8 days of daily injections was evaluated against Lantus in a euglycemic clamp study of patients with T1DM (N=30) receiving injections of 0.4 U/kg once daily. The dose on day 8 was followed by a 36-hour euglycemic clamp.2
This PK/PD study describes the time course effect following Toujeo administration.
Study Design
Clamp Study I: The pharmacodynamics of Toujeo at steady state after 8 days of daily injections was evaluated against Lantus in a euglycemic clamp study of patients with T1DM (N=30) receiving injections of 0.4 U/kg once daily. The dose on day 8 was followed by a 36-hour euglycemic clamp.2
ADA, American Diabetes Association; BG, blood glucose; GIR, glucose infusion rate; PD, pharmacodynamics; PK, pharmacokinetics; T1DM, type 1 diabetes mellitus.
Select a patient with Type 1 or Type 2 Diabetes below to see efficacy and safety results from the 4 EDITION clinical studies
EDITION 11,4T2DM: Previously on basal and mealtime insulin ± metformin (N=804)
Mean A1C change at 26 weeks (vs -0.87% for Lantus*)
Incidence of severe hypoglycemia†
Incidence of hypoglycemia‡
EDITION 21,5T2DM: Previously on basal insulin and OADs (N=808)
Mean A1C change at 26 weeks (vs -0.70% for Lantus*)
Incidence of severe hypoglycemia†
Incidence of hypoglycemia‡
EDITION 31,6T2DM: Insulin-naive patients on OADs (N=862)
Mean A1C change at 26 weeks (vs -1.46% for Lantus*)
Incidence of severe hypoglycemia†
Incidence of hypoglycemia‡
EDITION 41,7T1DM: Previously on basal and mealtime insulin (N=546)
Mean A1C change at 26 weeks (vs -0.44% for Lantus*)
Incidence of severe hypoglycemia†
Incidence of hypoglycemia‡
There were no clinically important differences in body weight between treatment groups.1
OADs, oral antidiabetic drugs; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.
†Severe hypoglycemia: an event requiring assistance of another person to actively administer a resuscitative action.
‡Hypoglycemia defined as self-monitored or plasma glucose value <54 mg/dL regardless of symptoms.
Study Design
All studies were 26-week, open label, controlled, titrate-to-target, noninferiority studies in adults with diabetes not at A1C goal (range: 7% to 10% or 11%) randomized to Toujeo or Lantus once daily. All patients were titrated to an FPG goal of 80-100 mg/dL (T2DM) or 80-130 mg/dL (T1DM).1
Calculate the suggested starting dose for your patients with T2DM
View BRIGHT head-to-head study vs Tresiba